[關(guān)鍵詞]
[摘要]
目的 觀察甘海胃康膠囊聯(lián)合替普瑞酮治療慢性淺表性胃炎的臨床療效。方法 選取內(nèi)蒙古自治區(qū)中醫(yī)醫(yī)院2015年2月-2016年8月接診的慢性淺表性胃炎患者86例,隨機(jī)分為對照組和治療組,每組各43例。對照組飯后口服替普瑞酮膠囊,50 mg/次,3次/d;治療組在對照組的基礎(chǔ)上口服甘海胃康膠囊,6粒/次,3次/d。兩組患者均連續(xù)治療3周。比較兩組臨床療效、胃黏膜修復(fù)和中醫(yī)證候評分情況。結(jié)果 治療后,對照組和治療組總有效率分別為86.05%和93.02%,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組患者胃黏膜修復(fù)和中醫(yī)證候評分均較治療前明顯降低,同組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。且與對照組相比,治療組上述評分降低的更顯著,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 甘海胃康膠囊聯(lián)合替普瑞酮治療慢性淺表性胃炎臨床療效確切,癥狀改善明顯,具有一定的臨床推廣應(yīng)用價(jià)值。
[Key word]
[Abstract]
Objective To observe the clinical curative effect of Ganhai Weikang Capsules combined with teprenone in treatment of chronic superficial gastritis. Methods Patients (86 cases) with chronic superficial gastritis in Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine from February 2015 to August 2016 were randomly divided into the control and treatment groups, and each group had 43 cases. The patients in the control group were po administered with Teprenone Capsules, 50 mg/time, three times daily. The patients in the treatment group were po administered with Ganhai Weikang Capsules on the basis of the control group, 6 grains/time, three times daily. After treatment, the clinical efficacy, gastric mucosal repair and TCM syndrome scores in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment group were 86.05% and 93.02%, respectively, and there were differences between two groups (P<0.05). After treatment, gastric mucosal repair and TCM syndrome scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And compared with the control group, these scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Ganhai Weikang Capsules combined with teprenone has an obvious curative effect in treatment of chronic superficial gastritis with significantly improved symptoms, which has a certain clinical application value.
[中圖分類號(hào)]
[基金項(xiàng)目]